0001209191-18-007843.txt : 20180206
0001209191-18-007843.hdr.sgml : 20180206
20180206162646
ACCESSION NUMBER: 0001209191-18-007843
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180205
FILED AS OF DATE: 20180206
DATE AS OF CHANGE: 20180206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ros Matthew
CENTRAL INDEX KEY: 0001673802
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35945
FILM NUMBER: 18577910
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Epizyme, Inc.
CENTRAL INDEX KEY: 0001571498
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261349956
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-229-5872
MAIL ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-05
0
0001571498
Epizyme, Inc.
EPZM
0001673802
Ros Matthew
C/O EPIZYME, INC.
400 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Operating Officer
Commons Stock, par value $0.0001
2018-02-05
4
M
0
72264
9.58
A
74867
D
Commons Stock, par value $0.0001
2018-02-05
4
S
0
71745
16.6251
D
3122
D
Common Stock, par value $0.0001
2018-02-05
4
S
0
519
17.20
D
2603
D
Stock Option (Right to Buy)
9.58
2018-02-05
4
M
0
72264
0.00
D
2027-05-15
Common Stock
72264
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 per share to $17.15 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
This option is fully vested.
/s/ Adriana Sullivan, attorney-in-fact
2018-02-06